Publications by authors named "H Veelken"
Article Synopsis
- Tumours, especially in follicular lymphoma, show significant genetic and transcriptional diversity that influences cancer development and treatment strategies.
- The study introduces CaClust, an advanced model that combines various genomic data types to better understand tumor evolution and how genotypes translate into phenotypes.
- CaClust demonstrates improved performance over existing models and offers insights into mutations driving the disease, potential treatment targets, and confirms findings through single-cell analysis.
Given the rarity of primary central nervous system lymphoma (PCNSL), evaluations of different high-dose methotrexate-(HD-MTX)-based treatment regimens is sparse. This retrospective, multicenter study evaluates clinical characteristics and outcomes (progression-free, overall and disease-specific survival) after five HD-MTX-based polychemotherapeutic regimens and two consolidation therapies. 346 patients with histologically confirmed PCNSL, treated with ≥ 1 cycle HD-MTX-based strategies (≥3g/m/cycle) were included.
View Article and Find Full Text PDFThe diagnostic spectrum for AML patients is increasingly based on genetic abnormalities due to their prognostic and predictive value. However, information on the AML blast phenotype regarding their maturational arrest has started to regain importance due to its predictive power for drug responses. Here, we deconvolute 1350 bulk RNA-seq samples from five independent AML cohorts on a single-cell healthy BM reference and demonstrate that the morphological differentiation stages (FAB) could be faithfully reconstituted using estimated cell compositions (ECCs).
View Article and Find Full Text PDFThe degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
Leuk Lymphoma
September 2024
Cytokine release syndrome (CRS) occurs frequently after haplo-identical allogeneic stem cell transplantation (alloSCT) with post-transplant cyclophosphamide (PTCy), increasing nonrelapse mortality (NRM) and decreasing survival. Data on CRS in HLA-matched alloSCT are limited and effects of specific HLA-mismatches on CRS development unknown. We hypothesized that in HLA-matched alloSCT increasing degrees of HLA-mismatching influence CRS incidence, NRM and survival.
View Article and Find Full Text PDFArticle Synopsis
- Unmodified donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (alloSCT) can enhance the beneficial Graft-versus-Leukemia (GvL) effects but also pose a risk for severe Graft-versus-Host Disease (GvHD).
- Key factors influencing GvHD risk after DLI include patient-derived antigen-presenting cells, lymphocyte count, and recent viral infections, particularly in patients with acute leukemia or myelodysplastic syndrome.
- Results indicate that certain conditions, like the timing of DLI and mixed bone marrow chimerism, significantly impact the likelihood of developing GvHD, with those receiving DLI three months post-transplant facing higher risks associated with